Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe Haemophilia A (FVIII:C \< 1%)~* Male patients \>= 18 years of age~* Previous treatment with a FVIII concentrate for at least 150 EDs~* Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start~* Immunocompetence (CD4+ count \> 200/uL)~Exclusion Criteria:~* Any coagulation disorder other than Haemophilia A~* Present of past FVIII inhibitor activity~* Severe liver or kidney disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human-cl rhFVIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).